

PSC BIOTECH PARTNERSHIP EXPANDS US PHARMA SALES REACH

Adelaide, Australia, 14 October 2026: Leaders in AI microbiology automation, Clever Culture Systems Ltd (ASX: CC5) (**CCS** or the **Company**), is pleased to announce the appointment of PSC Biotech® Corporation (**PSC Biotech**) as the Sales Agent for APAS® Independence across the pharmaceutical manufacturing market in the United States, Canada and Singapore.

Highlights:

- **Opens a new pharmaceutical customer segment for APAS® Independence**, extending CCS's sales reach beyond its current direct focus on the Top-20 global pharmaceutical companies
- **Establishes an incremental and non-duplicative sales channel** targeting regional, medium and large pharmaceutical manufacturers
- **Preserves CCS's direct "Land & Expand" strategy** for strategically important global pharmaceutical accounts and multi-site enterprise opportunities
- **Leverages PSC Biotech's established customer relationships**, creating mutual value through success-based commissions on APAS® Independence sales and opportunities for PSC Biotech to provide professional services
- **CCS retains control of sale closure, instrument pricing and all recurring software and service revenue**
- **Will establish an APAS® Independence Centre of Excellence** at PSC Biotech's BioTechnique CDMO facility in Pennsylvania, with one APAS® Independence committed for purchase

Investor call with CCS and PSC Biotech CEO's scheduled 15-Oct-26, 8:30am AEST [<Register here>](#)

Brent Barnes, CCS CEO and Managing Director said:

"We have successfully established APAS® Independence with leading global pharmaceutical manufacturers through our Land & Expand strategy which will continue to be a core focus for CCS. The PSC Biotech partnership provides a new, complementary and incremental channel to broaden our reach across the US pharmaceutical market, particularly into mid-tier and regional manufacturers that are outside our current direct-sales focus. We expect this market expansion to generate a meaningful increase in qualified sales opportunities over the coming 12 months, with APAS® Independence instrument sales converting from these opportunities from FY28 and beyond."

John Clapham, PSC Biotech Founder and CEO said:

"Our extensive relationships across the pharmaceutical industry provides a strong platform to introduce APAS® Independence to a much broader customer base. We see a significant opportunity to combine CCS's innovative technology with our pharmaceutical expertise and customer reach, creating new opportunities for both organisations while helping our customers improve the efficiency and quality of microbiological testing."

PSC Biotech adds a complementary sales channel alongside CCS's direct "Land & Expand" strategy

CCS has appointed PSC Biotech as the sole Sales Agent for APAS® Independence across the pharmaceutical manufacturing market in the United States, Canada and Singapore. Under the sales agent agreement (Sales Agent Agreement), PSC Biotech will identify and develop new sales opportunities for APAS® Independence through its established pharmaceutical customer network. Qualified sales opportunities will be referred to CCS, which retains responsibility for closing the sale. PSC Biotech will receive a commission on hardware sales. All ongoing software and service revenues will remain with CCS and excluded from the commission structure with PSC Biotech.

Over the past two years, CCS has successfully established APAS® Independence within the sterile drug manufacturing market, executing a Land and Expand strategy which targets the largest pharmaceutical companies globally. APAS® Independence is now being deployed and evaluated across a growing base of pharmaceutical manufacturers, including eight of the world's largest pharmaceutical companies. This provides significant commercial validation and an established platform from which CCS can expand adoption across individual customer networks and the broader pharmaceutical market. The

partnership with PSC Biotech is incremental to this strategy, providing an additional channel to broaden market awareness and reach without requiring CCS to build a larger corresponding sales organisation.

PSC Biotech is a global life sciences services company specialising in validation, engineering and regulatory consulting services to the pharmaceutical industry. Their expertise is providing consulting services, with over 500 employees globally, establishes them as a trusted partner to the greater than 1,000 customers served. They will leverage this network to identify and establish new sales opportunities for the APAS® Independence, which will also create new opportunities for PSC Biotech to further sell their validation capabilities, creating a strong mutually beneficial relationship. The partnership is expected to create a scalable additional source of qualified sales opportunities, providing an expected uplift to APAS® Independence instrument sales from FY28 onwards.

PSC Biotech to purchase 1 APAS® Independence instrument and establish a centre of excellence

As part of the Sales Agent Agreement, PSC Biotech has committed to purchase one APAS® Independence instrument for installation at its wholly owned Contract Drug Manufacturing (**CDMO**) business, BioTechnique, in York, Pennsylvania. BioTechnique is in the early stages of its growth trajectory, providing sterile fill-finish services ranging from early-stage clinical development through to commercial product manufacturing. APAS® Independence will be qualified and validated onsite for GMP use, providing a live pharmaceutical manufacturing environment for the technology and establishing a US centre of excellence for future product showcases, customer demonstrations and prospective customer evaluations.

Key Terms of the Sales Agent Agreement

- **Parties:** CCS and PSC Biotech.
- **Date and term:** The agreement was fully executed on 13th October 2026 and has an initial term of 36 months, with an option to extend 24 months by mutual agreement.
- **Scope and exclusivity:** PSC Biotech is CCS's sole Sales Agent for APAS® Independence in the pharmaceutical manufacturing market in the United States, Canada and Singapore. PSC Biotech is responsible to perform marketing and promotional activities for the APAS® Independence in those regions and refer qualified customer leads to CCS. During the term of the Sales Agent Agreement, CCS may not appoint another third party to provide such services in the nominated regions. CCS is not itself restricted or prevented from providing such services in those regions. CCS remains responsible for the sale of the APAS® products with the end customer.
- **Remuneration:** CCS will pay PSC Biotech a commission on APAS® Independence sales from accepted qualified opportunities referred by PSC Biotech. The commission is payable 30 days after CCS receiving payment from the customer.
- **APAS® Independence purchase:** PSC Biotech commit to raise a purchase order to buy one instrument within 90 days of contract signing.
- **Termination:** Either party may terminate the agreement by providing 3 months' written notice. The commission is payable by CCS to PSC Biotech for any sales to the agreed list of qualified customer leads, completed within 9 months of termination or expiry of the Sales Agent Agreement.

Investor Conference Call. Joint CEO's of CCS and PSC Biotech

The Company will hold a conference call at **8.30am AEDT on Thursday, 15 October 2026** to discuss the partnership and details covered in this announcement. The Company's CEO and Managing Director, Brent Barnes, will host the call and will be joined by PSC Biotech Founder and CEO, John Clapham.

All attendees must register to attend the call. Please register using the link below. After registering, you will receive a confirmation email about joining the webinar including options to attend via computer or telephone.

https://us06web.zoom.us/webinar/register/WN_pri7EGwuRo2RHez98Qvmow

A Q&A session will be held at the end of the conference call; to participate in this, you will need to join the conference via a computer. A recording of the call will be available on the Investor Centre section of the Company's website for 60 days after the call.

Approved for release by the CCS Board.

– ENDS –

About Clever Culture Systems

Clever Culture Systems (CCS) provides intelligent automation solutions to microbiology laboratories. Based in Adelaide, South Australia, the Company has developed a best-in-class technology, the Automated Plate Assessment System (APAS® Independence), using artificial intelligence and machine learning software to automate the imaging, analysis and interpretation of microbiology culture plates. The technology remains the only US FDA-cleared artificial intelligence technology for automated culture plate reading. The product is currently being sold to microbiology laboratories in the pharmaceutical manufacturing sector for the reading of environmental monitoring culture plates and to clinical laboratories as an in vitro diagnostic for infectious diseases. Thermo Fisher Scientific, Inc is exclusive distributor of the APAS® Independence to clinical customers in the United States and selected countries in Europe.

About PSC Biotech

Founded in 1996, PSC Biotech® has spent more than two decades providing life sciences with essential services to ensure that healthcare products are developed, manufactured, and distributed to the highest standards in compliance with all applicable regulatory requirements.

Since inception, PSC Biotech® has served as a strategic partner to emerging and established life science companies, all to help bring their life-saving products to market. PSC Biotech® operates in 52 countries globally and has served thousands of clients. Employing a global team of skilled professionals and experts that span strategically located offices in North America, Europe, Asia, and the Middle East, we are proud of the roles we have fulfilled to help our clients achieve success. www.biotech.com

INVESTOR ENQUIRIES

Clever Culture Systems
Brent Barnes Chief Executive Officer & Managing Director Tel: +61 8 8227 1555 E: info@cleverculturesystems.com